High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer

By Braunschweig I.   Mirza N.Q.   Rondon G.   Lauppe J.   Mehra R.   Gajewski J.   Körbling M.   Huh Y.O.   Geisler D.   Gee A.P.   Champlin R.   Przepiorka D.  

Cytotherapy, Vol. 2, Iss. 2, 2000-02 ,pp. : 105-110

Ashgate Publishing Ltd

Access to resources Recommend Favorite

The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma

By Hiwase Dk   Hiwase S.   Bailey M.   Bollard G.   Schwarer Ap  

Cytotherapy, Vol. 10, Iss. 5, 2008-01 ,pp. : 507-517

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis

By  

Current Stem Cell Research & Therapy, Vol. 6, Iss. 1, 2011-03 ,pp. : 16-28

Bentham Science Publishers

Access to resources Recommend Favorite

Lymphocyte recovery: an overlooked contribution to autologous stem cell transplant outcome

By Le Blanc K  

Cytotherapy, Vol. 10, Iss. 5, 2008-01 ,pp. : 441-442

Ashgate Publishing Ltd

Access to resources Recommend Favorite

CD4⁺⁺ CD28⁺⁺ lymphocytes on day 5 after high-dose melphalan for multiple myeloma predict a low risk of infections during severe neutropenia and are associated with the number of reinfused T lymphocytes of the autologous stem cell graft

By Schmidmaier Ralf   Then Cornelia   Schnabel Brigitte   Oduncu Fuat   Baumann Philipp   Straka Christian  

Cytotherapy, Vol. 13, Iss. 8, 2011-09 ,pp. : 987-992

Ashgate Publishing Ltd

Access to resources Recommend Favorite